Radioimmunotherapy represents a promising new treatment modality for patients with lymphoma. When used appropriately, RIT can induce responses in the majority of patients with limited nonhematopoietic toxicity, particularly when compared with standard chemotherapeutic regimens. Future studies will be required to better define the optimal place of RIT in the hematologist/ oncologist's armamentarium as well as the ideal dose, schedule, and potential for combination with other drugs. More importantly, randomized trials will be needed to determine whether RIT can truly alter the natural history of this group of diseases.

0 0

Post a comment